BioClinica, Inc. announced the launch of its new IVR/IWR (interactive voice response/interactive web response) platform, Trident IWR, at the 2010 Society for Clinical Data Management Annual Conference (SCDM). Trident IWR’s interface provides clinical operations personnel with an intuitive and faster way to directly set up, monitor, and maintain randomization and supplies for their clinical trials.
“We believe that Trident will fundamentally change the IVR/IWR market. Trident gives customers the ability to build complex trials in a quicker and less costly manner than previous alternatives which require the development of custom programming for each new clinical trial,” said Mark Weinstein, CEO of BioClinica.
Designed from inception as a web-based system, Trident simultaneously delivers IVR phone support through the same simplified configuration process. It is fully synchronized with BioClinica Optimizer a clinical supply simulation and visualization package. Study designs simulated in Optimizer can configure Trident IWR to precisely match the optimal scenario identified using Optimizer. After deployment, Trident data can update Optimizer, and then Optimizer can re-simulate and reforecast. BioClinica will conduct educational Trident-related webinars beginning in November 2010. For more information about these sessions please visit: http://www.bioclinica.com/webinars/.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.